Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
Open accessThe DOI matches its Crossref record; 384 of the 384 references it cites were found in a registry or an index.
Abstract
A panel of experts was convened by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) to update the 2010 clinical practice guideline on Clostridium difficile infection (CDI) in adults. The update, which has incorporated recommendations for children (following the adult recommendations for epidemiology, diagnosis, and treatment), includes significant changes in the management of this infection and reflects the evolving controversy over best methods for diagnosis. Clostridium difficile remains the most important cause of healthcare-associated diarrhea and has become the most commonly identified cause of healthcare-associated infection in adults in the United States. Moreover, C. difficile has established itself as an important community pathogen. Although the prevalence of the epidemic and virulent ribotype 027 strain has declined markedly along with overall CDI rates in parts of Europe, it remains one of the most commonly identified strains in the United States where it causes a sizable minority of CDIs, especially healthcare-associated CDIs. This guideline updates recommendations regarding epidemiology, diagnosis, treatment, infection prevention, and environmental management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clostridium difficile is a Gram‐positive extracellular pathogen, which remains localized to the gastrointestinal tract but can cause severe toxin‐mediated gastrointestinal pathology, with a mortality rate of up to 6%. 67 , 68”
From The battle for iron in enteric infections (2020) · cites this paper as [68]
Citations
Cites
Multistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Stool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Self-citationBurden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641
Self-citationDethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361
An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Self-citationLoo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Self-citationGoing from evidence to recommendations
Guyatt, G. H., Oxman, A. D., Kunz, R., Falck-Ytter, Y., Vist, G. E., Liberati, A., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39493.646875.ae · Cited by 1,810
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Research works printed but not linked: 3
- Health Protection Agency, 2005, Outbreak of Clostridium difficile infection in a hospital in southeast England, CDR Wkly, 15
- Tleyjeh, 2012, Association between acid-suppression therapy and Clostridium difficile infection: a systematic review and meta-analysis, Clin Microbiol Infect, 18, 113
- Polage, 2015, Overdiagnosis of Clostridium difficile infection in the molecular test era, JAMA Intern Med, 175, 1792, 10.1001/jamainternmed.2015.4114 · DOI · Paper page
Cited by
Items 901–1,000 of 1,000
Small-Molecule Inhibition of the C. difficile FAS-II Enzyme, FabK, Results in Selective Activity
Jones, J. A., Prior, A. M., Marreddy, R. K. R., Wahrmund, R. D., Hurdle, J. G., Sun, D., & Hevener, K. E. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00293 · Cited by 13
A Tiered Approach for Preventing Clostridioides difficile Infection
Rohde, J. M., Jones, K. M., Padrón, N. A., Olmsted, R. N., Chopra, V., & Dubberke, E. R. (2019) · Annals of Internal Medicine · doi:10.7326/m18-3444 · Cited by 13
Self-citationDiagnostic Stewardship for Clostridiodes difficile Testing: From Laxatives to Diarrhea and Beyond
Rock, C., & Maragakis, L. L. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz982 · Cited by 13
Kuijper, E. J., Allegretti, J. R., Hawkey, P. M., Sokol, H., Goldenberg, S. D., Ianiro, G., Gasbarrini, A., Kump, P. K., Costello, S. P., Keller, J. J., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30545-6 · Cited by 12
Comparative Study of Clostridium difficile Clinical Detection Methods in Patients with Diarrhoea
Xiao, Y., Liu, Y., & Qin, X. (2020) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2020/8753284 · Cited by 13
“infection (CDI) in adults and children updated by the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) in 2017 [6].”
BackgroundBarker, A., Scaria, E., Alagöz, O., Sethi, A. K., & Safdar, N. (2020) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2020.14 · Cited by 14
Carlson, T. J., & Gonzales-Luna, A. J. (2020) · Current Infectious Disease Reports · doi:10.1007/s11908-020-00730-1 · Cited by 13
Kuenzli, A. B., Burri, S., Casanova, C., Sommerstein, R., Buetti, N., Seth-Smith, H. M. B., Bodmer, T., Egli, A., & Marschall, J. (2020) · Journal of Hospital Infection · doi:10.1016/j.jhin.2020.07.034 · Cited by 13
AbdelKhalek, A., & Seleem, M. N. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106188 · Cited by 14
Managing the Microbiome: How the Gut Influences Development and Disease
Weinstein, N., Garten, B., Vainer, J., Minaya, D. M., & Czaja, K. (2020) · Nutrients · doi:10.3390/nu13010074 · Cited by 15
Nicholson, M. R., Hourigan, S. K., Conrad, M. A., Goyal, A., Jensen, K., Kelsen, J. R., Kennedy, M., Weatherly, M., & Kahn, S. A. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001350 · Cited by 13
“INTRODUCTION Fecal microbiota transplantation (FMT) has been well studied for the treatment ofClostridioides difficile infection (CDI) in children and adults (1,2) and is included in recent practice guidelines for the treatment of recurrent CDI (3).”
BackgroundExternal Validation and Comparison of Clostridioides difficile Severity Scoring Systems
Perry, D. A., Shirley, D. K., Micić, D., Patel, P. C., Putler, R. K. B., Menon, A., Young, V. B., & Rao, K. K. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab737 · Cited by 15
Targeting Clostridioides difficile: New uses for old drugs
Chen, J., Li, Y., Wang, S., Zhang, H., Du, Y., Wu, Q., & Wang, H. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.03.021 · Cited by 15
Wu, X., Lai, X., Tu, H., Zou, H., & Cao, J. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.03.033 · Cited by 13
Levofloxacin prophylaxis in hospitalized children with leukemia: A cost‐utility analysis
Maser, B., Pelland‐Marcotte, M., Alexander, S. W., Sung, L., & Gupta, S. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28643 · Cited by 13
Schoyer, E., & Hall, K. K. (2020) · Journal of Patient Safety · doi:10.1097/pts.0000000000000749 · Cited by 12
Voth, E. R., Solanky, D., Loftus, E. V., Pardi, D. S., & Khanna, S. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284821997792 · Cited by 13
Trends in facility-level rates of Clostridioides difficile infections in US hospitals, 2019–2020
Rose, A. N., Baggs, J. M., Kazakova, S. V., Guh, A. Y., Yi, S. H., McCarthy, N. L., Jernigan, J. A., & Reddy, S. C. (2022) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2022.69 · Cited by 13
Dalal, R. S., Mitri, J., Goodrick, H., & Allegretti, J. R. (2022) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001733 · Cited by 12
Risk Factors Associated with Severe Clostridioides difficile Infection in Patients with Cancer
Francisco, D. M. A., Zhang, L., Jiang, Y., Olvera, A., Adachi, J. A., Guevara, E. Y., Aitken, S. L., Garey, K. W., Peterson, C. B., Do, K.-A., et al. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00722-9 · Cited by 14
“Current guidelines for the diagnosis and treatment/management of CDI [18] stratify therapy on the basis of disease severity.”
BackgroundSelf-citationMicrobiome therapeutics for the treatment of recurrent Clostridioides difficile infection
Bloom, P. P., & Young, V. B. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2154600 · Cited by 12
Chen, L. A., Oliva‐Hemker, M. M., Radin, A. S., Weidner, M., O’Laughlin, B., Sears, C. L., Javitt, N. B., & Hourigan, S. K. (2023) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjad057 · Cited by 15
Vintilă, B. I., Arseniu, A. M., Morgovan, C., Butucă, A., Sava, M., Bîrluțiu, V., Rus, L. L., Ghibu, S., Bereanu, A. S., Codru, I. R., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16111585 · Cited by 13
Sun, X., Zhou, X., He, W., Sun, W., & Xu, Z. M. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s443462 · Cited by 14
Feuerstadt, P., Allegretti, J. R., Dubberke, E. R., Guo, A. X., Harvey, A., Yang, M., García-Horton, V., Fillbrunn, M. K., Tillotson, G., Bancke, L. L., et al. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-023-00907-w · Cited by 15
Self-citationGuh, A. Y., Fridkin, S. K., Goodenough, D., Winston, L. G., Johnston, H. L., Basiliere, E., Olson, D. M., Wilson, C. D., Watkins, J. J., Korhonen, L. C., et al. (2024) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2023.262 · Cited by 12
Self-citationBachmann, I., Behrmann, O., Klingenberg-Ernst, M., Rupnik, M., Hufert, F. T., Dame, G., & Weidmann, M. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.3c02985 · Cited by 12
Guh, A. Y., Li, R., Korhonen, L. C., Winston, L. G., Parker, E., Czaja, C. A., Johnston, H. L., Basiliere, E., Meek, J. I., Olson, D. M., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae127 · Cited by 12
Self-citationFighting against Clostridioides difficile infection: Current medications
Quan, M., Zhang, X., Fang, Q., Lv, X., Wang, X., & Zong, Z. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107198 · Cited by 13
Exploring novel microbial metabolites and drugs for inhibiting Clostridioides difficile
Abouelkhair, A. A., & Seleem, M. N. (2024) · mSphere · doi:10.1128/msphere.00273-24 · Cited by 11
Probiotic use as prophylaxis for Clostridium difficile-associated diarrhea in a community hospital
Hudson, S. L., Arnoczy, G. S., Gibson, H., Thurber, C., Lee, J., & Kessell, A. (2019) · American Journal of Infection Control · doi:10.1016/j.ajic.2018.12.018 · Cited by 14
Zacharioudakis, I. M., Zervou, F. N., Shehadeh, F., Mylona, E. K., & Mylonakis, E. E. (2019) · EClinicalMedicine · doi:10.1016/j.eclinm.2019.02.001 · Cited by 12
“difficile on an unformed stool specimen collected N3 days after hospital admission [5].”
BackgroundBorsky, A. E., Flores, E. J., Berliner, E., Chang, C., Umscheid, C. A., & Chang, S. (2019) · Journal of Hospital Medicine · doi:10.12788/jhm.3157 · Cited by 13
Prevention and treatment of recurrent Clostridioides difficile infection
Shin, J. H., & Warren, C. A. (2019) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000587 · Cited by 12
Rhea, S. K., Hilscher, R., Rineer, J. I., Muñoz, B., Jones, K., Endres‐Dighe, S. M., DiBiase, L., Sickbert-Bennett, E. E., Weber, D. J., MacFarquhar, J., et al. (2019) · Health Security · doi:10.1089/hs.2019.0021 · Cited by 13
Risk Factors for Recurrent Community-associated Clostridiodes Difficile Infection in Children
Parmar, D. D., Dang, R., Miranda-Katz, M., Alabaster, A. L., & Greenhow, T. L. (2019) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002439 · Cited by 12
“On multivariable analyses, IBD and malignancy diagnoses were risk factors for rCA-CDI, which is supported in other CDI studies.(11,12) The strongest risk for recurrence was found in children with concurrent IBD with a 31.”
BackgroundMethodResultInfluentialFecal microbiota transplant for C. difficile infection: Just say yes
Cammarota, G., Gallo, A., & Bibbò, S. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.102109 · Cited by 17
Maruyama, H., Kusachi, S., Makino, H., Kanno, H., Yoshida, H., & Niitsuma, T. (2020) · Journal of Nippon Medical School · doi:10.1272/jnms.jnms.2020_87-403 · Cited by 12
Piekarska, A., Panasiuk, A., & Stępień, P. M. (2020) · Przeglad Epidemiologiczny · doi:10.32394/pe.74.06 · Cited by 12
Shaffer, S. R., Witt, J. C., Targownik, L. E., Kao, D. H., Lee, C., Smieliauskas, F., Rubin, D. T., Singh, H., & Bernstein, C. N. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.09.025 · Cited by 12
Increases in Anti-infective Drug Prices, Subsequent Prescribing, and Outpatient Costs
Lee, J. S., Joo, H., Maskery, B. A., Alpern, J. D., Park, C., Weinberg, M. S., & Stauffer, W. M. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.13963 · Cited by 12
Paschos, P., Ioakim, K., Malandris, K., Koukoufiki, A., Nayfeh, T., Akriviadis, E. A., Τσάπας, Α., & Bekiari, E. (2021) · Anaerobe · doi:10.1016/j.anaerobe.2021.102441 · Cited by 13
Medicare Prescription Plans Limit Access to Recommended Drugs for Clostridioides difficile Infection
Buehrle, D. J., & Clancy, C. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab898 · Cited by 12
Lee, P., Chang, T.-E., Wang, Y., Lee, K., Lin, Y.-T., Chiou, J.-J., Huang, C.-W., Yang, U., Li, F.-Y., Huang, H., et al. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.11.001 · Cited by 13
Sato, T., Kudo, D., & Kushimoto, S. (2022) · Surgical Infections · doi:10.1089/sur.2022.030 · Cited by 10
Sweeney, J. R., Crawford, C. V., & Yantiss, R. K. (2022) · Histopathology · doi:10.1111/his.14702 · Cited by 12
Perić, A. V., Rančić, N., Dragojevic-Simic, V. M., Milenković, B., Ljubenović, N., Rakonjac, B., Begović-Kuprešanin, V., & Šuljagić, V. (2022) · Antibiotics · doi:10.3390/antibiotics11091178 · Cited by 13
“Since 2017, according to the guidelines, fidaxomicin and vancomycin are the cornerstones of CDI treatment [36].”
BackgroundMethodDai, J., Gong, J., & Guo, R. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03376-1 · Cited by 12
“As a result, the “Infectious Diseases Society of America (IDSA) and Society of Healthcare Epidemiology (SHEA) CDI guidelines–2017 update” has included fidaxomicin as one of the recommended agents for the treatment of initial episodes of CDI [8].”
BackgroundChopra, T. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2171986 · Cited by 15
“oral vancomycin followed by rifaximin, or fidaxomicin [5].”
BackgroundSaruta, Y., Watanabe, K., Tsuji, T., Takahashi, Y., Matsuzawa, H., Yoshida, T., Takahashi, S., Shimodaira, Y., Matsuhashi, T., & Iijima, K. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16169 · Cited by 14
Fecal Microbiota Transplant in Pediatric Solid Organ Transplant Recipients
Rodig, N., Weatherly, M., Kaplan, A. L., Ballal, S. A., Elisofon, S. A., Daly, K. P., & Kahn, S. A. (2023) · Transplantation · doi:10.1097/tp.0000000000004656 · Cited by 13
Vaughn, J. L., Balada-Llasat, J.-M., Lamprecht, M., Huang, Y., Anghelina, M. I., Boghdadly, Z. E., Bishop-Hill, K., Childs, R., Pancholi, P., & Andritsos, L. A. (2018) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000774 · Cited by 12
Schultz, K. M., Sickbert-Bennett, E. E., Marx, A. H., Weber, D. J., DiBiase, L., Campbell-Bright, S. L., Bode, L. E., Baker, M., Belhorn, T., Buchanan, M. O., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.00625-18 · Cited by 12
“Bolstered by evidence that repeat testing to detect CDI holds little value (9, 15), the microbiology laboratory also canceled tests ordered on patients with a negative C.”
BackgroundPouch, S. M., & Friedman‐Moraco, R. (2018) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2018.05.001 · Cited by 12
Fuchs, B. B., Tharmalingam, N., & Mylonakis, E. E. (2018) · Future Microbiology · doi:10.2217/fmb-2018-0157 · Cited by 13
Why do clinicians order inappropriate Clostridium difficile testing? An exploratory study
Kara, A. Y., Tahir, M., Snyderman, W., Brinkman, A., Fadel, W. F., & Dbeibo, L. (2018) · American Journal of Infection Control · doi:10.1016/j.ajic.2018.08.019 · Cited by 12
Skinner, A. M., Petrella, L. A., Siddiqui, F., Sambol, S. P., Gulvik, C. A., Gerding, D. N., Donskey, C. J., & Johnson, S. (2019) · Emerging infectious diseases · doi:10.3201/eid2602.181965 · Cited by 15
Self-citationMi, H., Bao, R., Xiao, Y., Yangwen, C., Sun, W., Shen, Y., Shi, Q., Chen, X., Lin, J., Hu, B., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00012 · Cited by 12
Vega, A. D., Heil, E. L., Blackman, A. L., Banoub, M. G., Johnson, J. K., Leekha, S., & Claeys, K. C. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2393 · Cited by 12
Bacteria producing antimicrobials against Clostridium difficile isolated from human stool
Khattab, R. A., Ahmed, N., Ragab, Y. M., & Rasmy, S. A. (2020) · Anaerobe · doi:10.1016/j.anaerobe.2020.102206 · Cited by 13
Szymczak, J. E., Muller, B. M., Shakamuri, N. S., Hamilton, K. W., Gerber, J. S., Laguio-Vila, M. R., Dumyati, G. K., Fridkin, S. K., Guh, A. Y., Reddy, S. C., et al. (2020) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2020.183 · Cited by 14
Diagnostic Stewardship for Comprehensive Gastrointestinal Pathogen Panel Tests
Baghdadi, J. D., Coffey, K., Leekha, S., Johnson, J. K., Diekema, D. J., & Morgan, D. J. (2020) · Current Infectious Disease Reports · doi:10.1007/s11908-020-00725-y · Cited by 13
“Clinical practice guidelines and expert reviews discourage testing formed stools for bacterial causes of infectious diarrhea [6, 9, 69].”
BackgroundHan, S., Yi, J., Kim, J., & Moon, H. (2020) · Microorganisms · doi:10.3390/microorganisms8060882 · Cited by 13
“difficile in patients with significant diarrhea, defined as unexplained and new-onset (≥3 unformed stools in 24 h) [12].”
BackgroundMild or Malign: Clinical Characteristics and Outcomes of Clostridium difficile Infection in Thailand
Imwattana, K., Putsathit, P., Leepattarakit, T., Kiratisin, P., & Riley, T. V. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01217-20 · Cited by 13
Girão, E. S., Tavares, B. D. M., dos Santos, S. A., Gamarra, G. L., Rizek, C., Martins, R. C. R., Neto, L. V. P., Diogo, C. L., Orsi, T. D. A., Espinoza, E. P. S., et al. (2020) · Anaerobe · doi:10.1016/j.anaerobe.2020.102267 · Cited by 12
Colonisation Factor CD0873, an Attractive Oral Vaccine Candidate against Clostridioides difficile
Karyal, C., Hughes, J., Kelly, M. L., Luckett, J., Kaye, P., Cockayne, A., Minton, N. P., & Griffin, R. (2021) · Microorganisms · doi:10.3390/microorganisms9020306 · Cited by 15
Badilla-Lobo, A., & Rodríguez, C. (2021) · Anaerobe · doi:10.1016/j.anaerobe.2021.102355 · Cited by 12
Systematic Literature Review on Burden of Clostridioides difficile Infection in India
Ghia, C. J., Waghela, S., & Rambhad, G. S. (2021) · Clinical Pathology · doi:10.1177/2632010x211013816 · Cited by 13
Johnson, T. M., Howard, A. H., Miller, M. A., Allen, L. L., Huang, M., Molina, K. C., & Bajrovic, V. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab294 · Cited by 12
“Certainly, updates made to the Infectious Diseases Society of America practice guidelines in 2017 affected MTZ and FDX use between our cohorts [21]; however, only 9% of the SoC cohort received MTZ monotherapy and subgroup analysis excluding these patients revealed similar findings as the overall population analysis.”
ResultAsgary, R. G., Snead, J. A., Wahid, N. A., Ro, V., Halim, M., & Stribling, J. (2021) · Emerging infectious diseases · doi:10.3201/eid2707.200209 · Cited by 12
Kim, J., Kim, J., Kim, B., & Pai, H. (2022) · Infection and Chemotherapy · doi:10.3947/ic.2022.0027 · Cited by 17
Floria, D., Obeidat, M., Váncsa, S., Kávási, S. B., Földvári-Nagy, L., Hegyi, P. J., Veres, D. S., Drug, V. L., & Erőss, B. M. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2562341 · Cited by 12
“12,13 Treatment with PPIs has also been hypothesized to increase the risk for developing small intestinal bacterial overgrowth (SIBO).”
Pediatric Clostridioides difficile Infection: Diagnosis and Diagnostic Stewardship
Schwenk, H. T., Pollock, N. R., & Vaughan-Malloy, A. M. (2021) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piab054 · Cited by 11
Du, H. Y., Siah, K. T. H., Zhang, V. R., Teh, R., Tan, C. Y. E., Yeung, W. L. K., Scaduto, C., Bolongaita, S., Kasunuran-Cruz, M. T., Liu, M., et al. (2021) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2021-000761 · Cited by 13
Diagnostic stewardship: what impacts antibiotics use?
Coffey, K., Morgan, D. J., & Claeys, K. C. (2023) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000927 · Cited by 11
“Copyright © 2023 Wolters Kluwer H unformed stools within 24h and not on laxatives within the preceding 48h) or a multistep algorithm with a combination of toxin enzyme immune assay, glutamate dehydrogenase and NAAT [17].”
MethodClostridioides Difficile in Latin America: An Epidemiological Overview
Morales-Olvera, C. G., Lanz-Zubiría, L., Aguilar-Zamora, E., Camorlinga‐Ponce, M., Aparicio‐Ozores, G., Aguilar-Zapata, D., Chávez-Tapia, N. C., Uribe, M., Barbero-Becerra, V. J., & Juárez-Hernández, E. (2023) · Current Microbiology · doi:10.1007/s00284-023-03475-x · Cited by 14
Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection
Feuerstadt, P., Crawford, C. V., Tan, X., Pokhilko, V., Bancke, L. L., Ng, S., Guthmueller, B., Bidell, M. R., Tillotson, G., Johnson, S., et al. (2023) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001947 · Cited by 13
Self-citationLi, X., Wang, Y., Cao, R., Xiao, F., Wang, X., Ye, L., Xiao, Y., Li, D., & Zhang, T. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s441312 · Cited by 11
Văcărean-Trandafir, I.-C., Amărandi, R.-M., Ivanov, I. C., Dragos, L. M., Mențel, M., Iacob, Ș., Mușină, A.-M., Bărgăoanu, E.-R., Roată, C. E., Morărașu, Ș., et al. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1468645 · Cited by 13
Leal, S. M., Popowitch, E. B., Levinson, K. J., John, T. M., Lehman, B., Rios, M. B., Gilligan, P. H., & Miller, M. B. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01885-17 · Cited by 11
“NAAT-only advocates utilizing strict preanalytic restrictions recommended by guidelines of the Infectious Diseases Society of America (IDSA) (32) may choose to take advantage of the high sensitivity of the GPP and report only detection of the C. difficile toxin gene for samples with MFI values of 150.”
MethodDemir, K. K., Cheng, M. P., & Lee, T. C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207128 · Cited by 11
Dinh, A., Monnier, A. L., Emery, C., Alami, S., Torreton, E., Duburcq, A., & Barbier, F. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03552-9 · Cited by 11
Drapkina, O. M., & Kaburova, A. N. (2020) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2020-04-02 · Cited by 14
“Известно, что к настоящему времени данная процедура уже признана эффективной терапией тяжелых форм кишечной клостридиальной инфекции [65].”
Elgendy, S., Aly, S. A., El-Hamid, R. F. A., Deaf, E., Faddan, N. H. A., & Hameed, M. R. A. (2020) · Iranian Journal of Microbiology · doi:10.18502/ijm.v12i4.3932 · Cited by 11
Menon, A., Perry, D. A., Motyka, J., Weiner, S., Standke, A. K., Penkevich, A., Keidan, M., Young, V. B., & Rao, K. K. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1395 · Cited by 11
Changing Results to Change Results: Nudging Antimicrobial Prescribing for Clostridium difficile
Herman, D. J., Sarabia, A., Chan, H., & Graham, C. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa605 · Cited by 11
“Analytic interventions are often the focus, but postanalytic interventions such as this are not mentioned but represent an additional avenue for research [7].”
BackgroundKarlovich, N. S., Sata, S. S., Griffith, B., Coop, A., Kalu, I. C., Engemann, J. J., Seidelman, J., Turner, N., Polage, C. R., Smith, B. A., et al. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.228 · Cited by 11
Lee, J., Chiu, C.-W., Tsai, P., Lee, C.-C., Huang, I., Ko, W., & Hung, Y. (2021) · Bioscience of Microbiota Food and Health · doi:10.12938/bmfh.2021-049 · Cited by 11
Bogdanová, K., Doubravská, L., Vágnerová, I., Hricová, K., Pudová, V., Röderová, M., Papajk, J., Uvízl, R., Langová, K., & Kolář, M. (2021) · Life · doi:10.3390/life11111127 · Cited by 13
Pitcher, N. P., Harjani, J. R., Zhao, Y., Jin, J., Knight, D. R., Li, L., Putsathit, P., Riley, T. V., Carter, G. P., & Baell, J. B. (2022) · ACS Omega · doi:10.1021/acsomega.1c06294 · Cited by 12
Effects of Low-dose and High-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy
Tan, W., Wang, J., Shi, P., Feng, L., Shi, J., Ning, B.-F., Yuan, Z.-L., Zeng, X. Y., & Xie, W. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00457 · Cited by 11
Nivet, C., Duhalde, V., Beaurain, M., Delobel, P., Quelven, I., & Alric, L. (2022) · The journal of nutrition health & aging · doi:10.1007/s12603-022-1756-1 · Cited by 13
“Many risk factors for infection have been identified and are more frequently found in the older people including hospitalisation, exposure to chemotherapy, antibiotic therapy and proton pump inhibitor (PPI) therapy (1).”
InfluentialNajafi-Ghalehlou, N., Feizkhah, A., Mobayen, M., Pourmohammadi-Bejarpasi, Z., Shekarchi, S., Roushandeh, A. M., & Roudkenar, M. H. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10383-3 · Cited by 13
Wei, S., Jespersen, M. L., Baunwall, S. M. D., Myers, P. N., Smith, E. M., Dahlerup, J. F., Rasmussen, S., Nielsen, H. B., Licht, T. R., Bahl, M. I., et al. (2022) · Microbiome · doi:10.1186/s40168-022-01394-w · Cited by 14
“This also explains the high recurrence rates observed following guideline-adherent treatment of patients with CDI, using vancomycin or fidaxomicin [4, 5].”
BackgroundClostridioides difficile resistance to antibiotics, including post-COVID-19 data
Boyanova, L., Dimitrov, G., Gergova, R. T., Hadzhiyski, P., & Markovska, R. D. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2252331 · Cited by 13
Rubin, Z., Martin, E. M., & Allyn, P. R. (2018) · Current Infectious Disease Reports · doi:10.1007/s11908-018-0639-4 · Cited by 12
Morgan, J. R., Carey, K., Barlam, T. F., Christiansen, C. L., & Drainoni, M. (2018) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002117 · Cited by 11
Yoo, I. Y., Song, D. J., Huh, H. J., & Lee, N. Y. (2018) · Annals of Laboratory Medicine · doi:10.3343/alm.2019.39.2.214 · Cited by 11
“However, a multiple-step algorithm for CDI diagnosis that includes a glutamate dehydrogenase (GDH) assay and toxin A/B assay as a screening test, along with a nucleic acid amplification test (NAAT), has recently been recommended [6, 7].”
Qutub, M., Govindan, P., & Vattappillil, A. (2019) · Medical Sciences · doi:10.3390/medsci7010006 · Cited by 11
Ridinilazole for the treatment ofClostridioides difficileinfection
Carlson, T. J., Endres, B. T., Bassères, E., Gonzales-Luna, A. J., & Garey, K. W. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1582640 · Cited by 13
Self-citation
Metadata
- Authors
- McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., Loo, V., Shaklee Sammons, J., Sandora, T. J., & Wilcox, M. H.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Edward Hines, Jr. VA Hospital (US)
- Loyola University Medical Center (US)
- St. Luke's Hospital (US)
- Johns Hopkins University (US)
- Children's Hospital of Philadelphia (US)
- Washington University in St. Louis (US)
- University of Houston (US)
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
- McGill University Health Centre (CA)
- Children’s Hospital of Philadelphia, Pennsylvania
- Boston Children's Hospital (US)
- Leeds Teaching Hospitals NHS Trust (GB)
- Corresponding author
- McDonald, L Clifford
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-02-15
- Volume
- 66
- Issue
- 7
- Pages
- e1-e48
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC6018983
- OpenAlex
- W2791326569
- Cited by
- 2,690
- References
- 383
- Citations by year
- 2026: 148 · 2025: 179 · 2024: 215 · 2023: 305 · 2022: 331 · 2021: 423 · 2020: 486 · 2019: 408 · 2018: 185
- FWCI
- 228.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- Funders
- Agency for Health Research and Quality
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Keywords
- Clostridium difficile infection, nosocomial infections, healthcare-associated diarrhea, pediatric infection, diagnosis, treatment, infection control, environmental management, ribotype 027, community-acquired infections, epidemiology
- MeSH terms
- Adult, Child, Clostridium Infections, Diarrhea, Humans, Retrospective Studies, Societies, Societies, Medical, Clostridioides difficile, Infectious Disease Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.